M A Ezzel Arab
NHTMRI, Egypt
Title: Direct acting antivirals and hepatocellular carcinoma correlations
Biography
Biography: M A Ezzel Arab
Abstract
Hepatocellular Carcinoma (HCC) is increasing worldwide and particularly in Egypt, where the prevalence of hepatitis C viral (HCV) infection, a well-established HCC risk factor, is the highest in the world. Direct-acting antivirals (DAAs) have completely changed the panorama of hepatitis C due to their high efficacy and optimal safety profile. The impact of DAA-based treatment on the incidence of HCC in patients with cirrhosis and particularly on the incidence of HCC recurrence after successful curative treatment has emerged as a controversial issue with potential clinical implications. As Egypt achieved the highest number (>1.5 million) of treated patients by DAAs globally up till now, it is so important to evaluate its situation in this issue. The talk will highlight on the following items: Discrepancy regarding the occurrence and recurrence of HCC, highlight on some Egyptian studies and possible factors contributing to increased HCC incidence/recurrence by DAAs.